C05C Capillary stabilizing agents
ATC group of level 3 – pharmacological subgroup · in plain English: medicines for piles and varicose veins
This site has the patient leaflet or the SPC of 1 medicine in this group and its subgroups.
- 1 prescription only (POM)
Active substance: Oxerutins – all medicines with this substance, also in combinations.
Place in the ATC classification
How to read ATC codes – what the levels mean and what a code does not tell you.
- C Cardiovascular system drugs 1,712 medicines
- C05 Vasoprotectives 38 medicines
- C05C Capillary stabilizing agents 1 medicine
- C05 Vasoprotectives 38 medicines
1 more subgroup has no medicine with a leaflet on this site.
Medicines in the group and its subgroups
| Medicine | Legal category |
|---|---|
| Paroven capsules 250 mg SPC (C05CA54 troxerutin, combinations) | Prescription only (POM) |
Other groups of the same level
Other names of the ATC group
- Czech: C05C Látky stabilizující kapiláry
- French: C05C médicaments agissant sur les capillaires
- German: C05C Kapillarstabilisierende Mittel
- Spanish: C05C Estabilizantes capilares (vasoprotectores)
- German: C05C Kapillarstabilisierende Mittel
- Polish: C05C Środki stabilizujące naczynia włosowate
- Turkish: C05C KAPİLER STABİLİZASYON AJANLARI
- Portuguese (Brazil): C05C AGENTES ESTABILIZADORES DOS VASOS CAPILARES
- Slovak: C05C Liečivá stabilizujúce kapiláry
- German (Switzerland): C05C Kapillarstabilisierende Mittel
- French (Switzerland): C05C Médicaments agissant sur les capillaires
- Dutch: C05C Capillairstabiliserende middelen
Sources
- Patient leaflets and SPCs: the MHRA product information (products.mhra.gov.uk) and the European Medicines Agency (EMA)
- Active substances, ATC codes and legal categories: the NHS Dictionary of Medicines and Devices (dm+d), NHS Business Services Authority
- World Health Organization (WHO): ATC/DDD classification, group C05C
Contains public sector information licensed under the Open Government Licence v3.0.
Ask your doctor or pharmacist which medicine is right for you.
